CONCLUSION
Wheezing occurs under the age of 5 for a variety of reasons. If the
patient with recurrent wheezing is evaluated well from the first
admission and treated according to wheezing after underlying diseases
such as gastroesophageal reflux, cystic fibrosis, ciliary dyskinesia,
cardiac and pulmonary anomalies are ruled out, both hospital admissions
and attacks will be prevented due to unnecessary treatments and
exacerbations of wheezing. In this study, it was observed that the
frequency of exacerbation was reduced by 90.9% in the first control
with the use of montelukast in the group with mAPI negative EVW. It was
seen that this effect continued in the 2nd control. With this study, we
believe montelukast may be a potential treatment option for EVW in
preschool children. This approach is an attractive therapeutic option
since it has the potential to reduce systemic steroid exposure and
hospitalizations. Studies with a larger patient population are needed to
better elucidate the role of montelukast in the management of EVW.